Skip to main content

Table 1 Characteristics of study participants by 2017 ACC/AHA and 2018 KSH guidelines and antihypertensive medication use

From: Differences in prevalence of hypertension subtypes according to the 2018 Korean Society of Hypertension and 2017 American College of Cardiology/American Heart Association guidelines: The Korean National Health and Nutrition Examination Survey, 2007–2017 (KNHANES IV-VII)

 Normal BP;Elevated BP;2018 KSH Guideline2017 ACC/AHA GuidelineTreated HTN
Prehypertension;Stage 1 HTN;Stage 2 HTN;Stage 1 HTN;Stage 2 HTN;
SBP <120 mmHgSBP 120–129 mmHgSBP 130–139 mmHgSBP 140–159 mmHgSBP ≥160 mmHgSBP 130–139 mmHgSBP ≥140 mmHg
&&ororororor
DBP <80 mmHgDBP < 80 mmHgDBP 80–89 mmHgDBP 90–99 mmHgDBP ≥100 mmHgDBP 80–89 mmHgDBP ≥90 mmHg
(n = 26,648)(n = 3406)(n = 11,336)(n = 5288)(n = 1392)(n = 11,336)(n = 6680)(n = 11,697)
% Study population48.5 (47.9–49.2)5.3 (5.0–5.5)20.4 (19.9–20.8)8.8 (8.5–9.1)2.3 (2.2–2.5)20.4 (19.9–20.8)11.1 (10.8–11.5)14.7 (14.3–15.1)
Male sex40.1 (39.5–40.8)54.7 (52.8–56.7)64.2 (63.2–65.2)66.9 (65.5–68.3)70.5 (67.8–73.2)64.2 (63.2–65.2)67.7 (66.4–68.9)47.6 (46.5–48.7)
Age, yrs39.7 (39.5–39.9)49.4 (48.6–50.3)45.0 (44.6–45.3)49.6 (49.1–50.1)50.0 (49.2–50.8)45.0 (44.6–45.3)49.7 (49.3–50.1)62.7 (62.5–63.0)
Smoking status
 Non-smoker61.0 (30.2–61.6)54.5 (52.3–56.6)45.4 (44.3–46.5)42.5 (40.9–44.1)37.0 (34.1–39.9)45.4 (44.3–46.5)41.3 (39.9–42.7)55.9 (54.8–57.0)
 Previous smoker12.1 (11.6–12.6)16.3 (14.7–17.9)17.9 (17.0–18.8)18.1 (16.8–19.4)22.0 (19.2–24.9)17.9 (17.0–18.8)18.9 (17.7–20.1)21.6 (20.6–22.5)
 Current smoker27.0 (26.3–27.7)29.2 (27.2–31.3)36.7 (35.6–37.9)39.4 (37.8–41.1)41.0 (38.0–43.9)36.7 (35.6–37.9)39.8 (38.3–41.2)22.5 (21.5–23.5)
Alcohol intake
 Non-drinker7.7 (7.3–8.1)12.4 (11.2–16.7)8.2 (7.7–8.8)9.8 (9.0–10.7)8.7 (7.1–10.2)8.2 (7.7–8.8)9.6 (8.8–10.3)19.6 (18.8–20.5)
 Former drinker34.0 (33.3–34.7)32.2 (30.2–34.1)26.3 (25.3–27.3)22.5 (21.2–23.9)19.6 (17.3–22.0)26.3 (25.3–27.3)21.9 (20.7–23.1)32.5 (31.5–33.5)
 Current drinker58.3 (57.5–59.0)55.4 (53.3–57.5)65.5 (64.4–66.6)67.7 (66.2–69.2)71.7 (69.0–74.4)65.5 (64.4–66.6)68.5 (67.2–69.9)47.9 (46.7–49.0)
Regular exercise
 Yes28.6 (28.0–29.5)29.9 (27.7–32.2)30.0 (28.8–31.2)28.8 (27.1–30.5)26.9 (23.9–29.8)30.0 (28.8–31.2)28.4 (26.9–29.9)24.4 (23.2–25.5)
 No71.4 (70.5–72.2)70.1 (67.8–72.3)70.0 (68.8–71.2)71.2 (69.5–72.9)73.1 (70.2–76.1)70.0 (68.8–71.2)71.6 (70.1–73.1)75.6 (74.5–76.8)
BMI, kg/m222.7 (22.7–22.8)24.0 (23.9–24.2)24.4 (24.3–24.5)25.1 (24.9–25.2)25.5 (25.3–25.8)24.4 (24.3–24.5)25.2 (25.0–25.3)25.3 (25.2–25.4)
Total cholesterol, mg/dL183.8 (183.3–184.3)190.6 (189.1–192.1)196.0 (195.2–196.8)200.0 (198.7–201.3)203.6 (201.4–205.8)196.0 (195.2–196.8)200.8 (199.6–201.9)187.0 (186.1–187.8)
HDL cholesterol, mg/dL51.7 (51.6–51.9)49.4 (48.9–49.9)49.1 (48.9–49.4)48.5 (48.1–48.9)48.2 (47.5–48.9)49.1 (48.9–49.4)48.4 (48.1–48.8)46.9 (46.6–47.1)
Triglyceride, mg/dL110.9 (109.7–112.2)137.8 (133.1–142.5)158.0 (154.5–161.5)178.0 (172.3–183.6)194.4 (184.6–204.3)158.0 (154.5–161.5)181.4 (176.5–186.4)160.2 (157.5–163.0)
Lipid-lowering agent intake1.9 (1.8–2.1)5.5 (4.7–6.4)2.8 (2.5–3.2)2.9 (2.4–3.4)1.7 (0.9–2.4)2.8 (2.5–3.2)2.6 (2.2–3.1)24.4 (23.4–25.3)
Fasting glucose, mg/dL93.1 (92.8–93.3)100.4 (99.4–101.3)99.0 (98.5–99.6)102.0 (101.2–102.8)104.9 (103.0–106.9)99.0 (98.5–99.6)102.6 (101.9–103.3)109.4 (108.8–110.1)
GFR, ml/min/1.73 m2101.8 (101.4–102.1)94.6 (93.9–95.4)96.3 (95.9–96.7)93.2 (92.6–93.7)91.8 (90.8–92.8)96.3 (95.9–96.7)92.9 (92.4–93.4)81.9 (81.5–82.3)
Diabetes mellitus4.0 (3.7–4.2)11.5 (10.3–12.8)7.8 (7.2–8.3)10.1 (9.1–11.0)10.7 (8.7–12.7)7.8 (7.2–8.3)10.2 (9.3–11.0)71.8 (70.8–72.9)
Chronic Kidney Disease0.7 (0.6–0.8)2.5 (1.9–3.0)1.0 (0.8–1.2)2.4 (2.0–2.9)2.9 (1.9–3.8)1.0 (0.8–1.2)2.5 (2.1–2.9)11.1 (10.4–11.8)
Mean 10-yr predicted ASCVD risk*
 High risk,*%, PCE2.0 (1.8–2.2)16.0 (14.6–17.3)6.5 (6.0–7.0)14.6 (13.6–15.6)19.1 (16.9–21.3)6.5 (6.0–7.0)15.5 (14.6–16.5)88.9 (88.2–89.6)
 High risk, *%, KRPM2.3 (2.2–2.5)11.8 (10.7–12.9)5.5 (5.1–5.9)11.3 (10.4–12.2)17.2 (15.0–19.4)5.5 (5.1–5.9)12.5 (11.6–13.4)88.9 (88.2–89.6)
History of CVD2.4 (2.2–2.6)6.9 (5.9–8.0)4.3 (3.8–4.8)4.7 (3.9–5.4)2.7 (1.9–3.5)4.3 (3.8–4.8)4.3 (3.7–4.9)21.3 (20.2–22.4)
  1. Values are presented as weighted % or mean (95% confidence interval)
  2. The study participants were grouped into the higher category of SBP and DBP. For example, if a person had SBP of 146 mmHg and DBP of 82 mmHg, they were grouped into the ≥140/90 mmHg category
  3. Abbreviations: ACC/AHA American College of Cardiology/American Heart Association, BMI Body mass index, CI Confidence interval, CKD Chronic kidney disease, CVD Cardiovascular disease, GFR Glomerular filtration rate, HDL High-density lipoprotein, HTN Hypertension, KRPM Korean Risk Prediction Model, KSH Korean Society of Hypertension, PCE Pooled Cohort Equation
  4. *10-yr risk was calculated among adults without a history of CVD
  5. *High risk defined as a 10-year predicted cardiovascular disease risk ≥10% or history of CVD